Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||KIT positive|
|Therapy||Imatinib + Letrozole|
|Indication/Tumor Type||breast cancer|
|Response Type||predicted - sensitive|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|KIT positive||breast cancer||predicted - sensitive||Imatinib + Letrozole||Phase 0||Actionable||In a pilot trial, Gleevec (imatinib mesylate) and Femara (letrozole) combination treatment resulted in clinical partial response in 90% (9/10) and stable disease in 10% (1/10) of the evaluable patients with invasive hormone-sensitive breast cancer, 8 of the 13 enrolled patients had KIT-positive tumors (PMID: 18248884).||18248884|
|PubMed Id||Reference Title||Details|
|(18248884)||Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer.||Full reference...|